Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. Dudani, S., Gan, C., Wells, C., Bakouny, Z., Dizman, N., Pal, S. K., Wood, L., Kollmannsberger, C. K., Szabados, B., Powles, T., Beuselinck, B., Donskov, F., Hansen, A., Bjarnason, G. A., Canil, C. M., Srinivas, S., Agarwal, N., Liow, E., Choueiri, T. K., Heng, D. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368302318